11,465 Shares of Danaher Corporation $DHR Acquired by Investment Planning Advisors Inc.

Investment Planning Advisors Inc. purchased a new position in Danaher Corporation (NYSE:DHR) in the third quarter, HoldingsChannel reports. The institutional investor purchased 11,465 shares of the conglomerate’s stock, valued at approximately $2,540,000. Danaher makes up approximately 0.6% of Investment Planning Advisors Inc.’s holdings, making the stock its 21st biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Danaher during the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP increased its stake in shares of Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after buying an additional 1,542,310 shares during the period. Jupiter Topco LLC bought a new position in shares of Danaher during the second quarter valued at about $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher in the 2nd quarter worth approximately $1,287,949,000. Finally, Bank of America Corp DE purchased a new position in Danaher during the 2nd quarter valued at $993,846,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock traded up $1.60 during trading hours on Wednesday, reaching $224.44. The company’s stock had a trading volume of 1,963,388 shares, compared to its average volume of 4,448,790. The firm has a 50 day moving average price of $212.41 and a 200-day moving average price of $195.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market cap of $157.78 billion, a P/E ratio of 39.86, a P/E/G ratio of 2.78 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 EPS. On average, analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. UBS Group began coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. TD Cowen lifted their target price on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim increased their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Evercore restated an “outperform” rating and set a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Finally, Barclays raised their target price on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $235.41.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.